Clinical, epidemiological, and laboratory profiles of bacterial infection or colonization among patients hospitalized in COVID-19 and non-COVID-19 intensive care units (ICUs) in Southeast Pará
DOI:
https://doi.org/10.11606/issn.2176-7262.rmrp.2023.204460Keywords:
COVID-19, Coinfection, Multidrug resistance, Evidence-based medicine, Intensive care unitsAbstract
Objectives: To compare the clinical, epidemiological, and laboratory profiles of bacterial infection or colonization among patients hospitalized in COVID-19 and non-COVID-19 intensive care units (ICUs) in Southeast Pará, Brazil. Methods: This was a retrospective analytical study based on the analyses of electronic medical records and microbiological reports of patients admitted to the ICU of a regional hospital located in Pará in the Brazilian Amazon due to complications associated with COVID-19 and other causes from March 2020 to December 2021. The sample consisted of data from the medical records of 343 patients collected after approval by the ethics and research committee (opinion number 5281433)
was granted. The data extracted from the bacteriological and antibiogram culture reports were analyzed to characterize the clinical-epidemiological profile of the patients. The data were transferred and tabulated in Microsoft Excel 2019 to conduct a descriptive analysis, and the associated statistical analyses were performed using Stata 17.0 statistical software. Results: Of the total patients, 59.5% were hospitalized in the COVID-19 ICU and 40.5% were hospitalized in the non-COVID-19 ICU. Most individuals admitted to the COVID-19 ICU and non-COVID-19 ICU were aged between 66 and 78 years and between 54 and 66 years, respectively. The hospitalization duration in the COVID-19 ICU was fewer than 15 days, whereas that in the non COVID-19 ICU was 15 to 30 days. Deaths were more frequent in the Covid-19 ICU compared to the non-Covid-19 ICU (64% versus 41%). In contrast, hospital discharge was more frequent in the non-Covid-19 ICU (58.3% versus 34.8%).The most prevalent comorbidity in both ICUs was circulatory system disease. Gram-negative bacteria were the most frequent etiological agent in both groups and were present in 63.1% of the cultures analyzed. Regarding the phenotypic profile of resistance, carbapenemase production was detected in 43.0% of the cultures analyzed. Multidrug resistance against antimicrobial drugs was more frequent in the non-COVID-19 ICU
(55.7%). Most of the antimicrobial drug prescriptions for were empirical. Conclusions: The recurrence of secondary infections and bacterial colonization in both COVID-19 and non-COVID-19 ICU patients should not be underestimated. The clinical, microbiological, and bacterial resistance profiles elucidated in this study highlight the need to develop and implement holistic and assertive strategies to control and mitigate these problems. Which will contribute to an improved prognosis for patients and quality of life patients.
Downloads
References
World Health Organization. Antimicrobial resistance [Internet]. Who.int. World Health Organization: WHO; 2021. Available from: https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance
Barber S, Sutherland N. DEBATE PACK O’Neill Review into Antibiotic Resistance [Internet]. 2017. Available from: https://researchbriefings.files.parliament.uk/documents/CDP-2017-0074/CDP-2017-0074.pdf
Nicola M, Alsafi Z, Sohrabi C, et al. The socio-economic implications of the coronavirus and COVID-19 pandemic: a review. Int J Surg. 2020;78(78):185–93. https://doi.org/10.1016/j.ijsu.2020.04.018.
Knight GM, Glover RE, McQuaid CF, et al. Antimicrobial resistance and COVID-19: intersections and implications. eLife. 2021;10(1):1–27. https://doi.org/10.7554/eLife.64139.
Bhullar K, Waglechner N, Pawlowski A, Koteva K, Banks ED, Johnston MD, et al. Antibiotic Resistance Is Prevalent in an Isolated Cave Microbiome. PLoS ONE. 2012;7(4):1–11. https://doi.org/10.1371/journal.pone.0034953.
World Health Organization. 10 global health issues to track in 2021 [Internet]. www.who.int. 2020. Available from: https://www.who.int/news-room/spotlight/10-global-health-issues-to-track-in-2021#:~:text=Speed%20up%20access%20to%20COVID
Mimura K, Oka H, Sawano M. A perspective on hospital-acquired (nosocomial) infection control of COVID-19: usefulness of spatial separation between wards and airborne isolation unit. Journal of Breath Research. 2021;15(4):042001. https://doi.org/10.1088/1752-7163/ac1721.
Provenzano BC, Bartholo T, Ribeiro-Alves M, Santos APGD, Mafort TT, Castro MCS de, et al. The impact of healthcare-associated infections on COVID-19 mortality: a cohort study from a Brazilian public hospital. Revista Da Associacao Medica Brasileira. 2021;67(7):997–1002. https://doi.org/10.1590/1806-9282.20210433.
Ribeiro EA, Gales AC, Oliveira APS de, Coelho DD, Oliveira RA de, Pfrimer IAH, et al. Molecular epidemiology and drug resistance of Acinetobacter baumannii isolated from a regional hospital in the Brazilian Amazon region. Revista da Sociedade Brasileira de Medicina Tropical. 2021;54(1):1–5. https://doi.org/10.1590/0037-8682-0087-2020.
Instituto Brasileiro de Geografia e Estatística. Pará | Cidades e Estados | IBGE [Internet]. www.ibge.gov.br. 2021. Available from: https://www.ibge.gov.br/cidades-e-estados/pa/
Hospital Regional Público do Araguaia. Hospital Regional Público do Araguaia [Internet]. HRPA. 2021. Available from: https://www.hrpa.org.br/
Brazilian Committee on Antimicrobial Susceptibility Testing. BR Cast [Internet]. BrCAST. 2021. Available from: http://brcast.org.br/documentos/
Magiorakos A-P, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clinical Microbiology and Infection: the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases. 2012;18(3):268–81. https://doi.org/10.1111/j.1469-0691.2011.03570.x.
Agência Nacional de Vigilância Sanitária. Série Segurança do Paciente e Qualidade em Serviços de Saúde Critérios Diagnósticos de Infecção Relacionada à Assistência à Saúde [Internet]. 2013. Available from: https://bvsms.saude.gov.br/bvs/publicacoes/criterios_diagnosticos_infeccoes_assistencia_saude.pdf
Martín-Aspas A, Guerrero-Sánchez FM, García-Colchero F, Rodríguez-Roca S, Girón-González J-A. Differential characteristics of Acinetobacter baumannii colonization and infection: risk factors, clinical picture, and mortality. Infection and Drug Resistance. 2018;11(1):861–72. https://doi.org/10.2147/idr.s163944.
Leekha S, Terrell CL, Edson RS. General Principles of Antimicrobial Therapy. Mayo Clinic Proceedings. 2011;86(2):156–67. https://doi.org/10.4065/mcp.2010.0639.
Agência Nacional de Vigilância Sanitária. Diretriz Nacional para Elaboração de Programa de Gerenciamento do Uso de Antimicrobianos em Serviços de Saúde. GVIMS/GGTES/ANVISA [Internet]. 2017. Available from: http://antigo.anvisa.gov.br/documents/33852/271855/Diretriz+Nacional+para+Elabora%C3%A7%C3%A3o+de+Programa+de+Gerenciamento+do+Uso+de+Antimicrobianos+em+Servi%C3%A7os+de+Sa%C3%BAde/667979c2-7edc-411b-a7e0-49a6448880d4?version=1.0
World Health Organization. Antimicrobials tewrdship programmes in health-care facilities in low-and middle-income countries a who practical toolkit antimicrobial stewardship [Internet]. 2019. Available from: https://apps.who.int/iris/bitstream/handle/10665/329404/9789241515481-eng.pdf
Huang H, Chen B, Liu G, Ran J, Lian X, Huang X, et al. A multi-center study on the risk factors of infection caused by multi-drug resistant Acinetobacter baumannii. BMC Infectious Diseases. 2018;18(1):1–6. https://doi.org/10.1186/s12879-017-2932-5.
Ribeiro EA, Carneiro TL, Andrade AL, Alves JAG. Ocorrência de contaminações por bactérias multirresistentes em leitos hospitalares na Amazônia durante a pandemia de COVID-19. Saúde (Santa Maria). 2021;47(1):1–14. https://doi.org/10.5902/2236583463270.
Hoang S, Georget A, Asselineau J, Venier A-G, Leroyer C, Rogues AM, et al. Risk factors for colonization and infection by Pseudomonas aeruginosa in patients hospitalized in intensive care units in France. PLoS One. 2018;13(3):e0193300. https://doi.org/10.1371/journal.pone.0193300.
Falcone M, Tiseo G, Giordano C, Leonildi A, Menichini M, Vecchione A, et al. Predictors of hospital-acquired bacterial and fungal superinfections in COVID-19: a prospective observational study. Journal of Antimicrobial Chemotherapy. 2020;76(4):1078–84. https://doi.org/10.1093/jac/dkaa530.
Blot S, Ruppé E, Harbarth S, Asehnoune K, Poulakou G, Luyt C-E, et al. Healthcare-associated infections in adult intensive care unit patients: Changes in epidemiology, diagnosis, prevention and contributions of new technologies. Intensive and Critical Care Nursing. 2022;70(1):103227. https://doi.org.10.1016/j.iccn.2022.103227.
Abbas, M., Robalo Nunes, T., Martischang, R. et al. Nosocomial transmission and outbreaks of coronavirus disease 2019: the need to protect both patients and healthcare workers. Antimicrob Resist Infect Control 10, 7 (2021). https://doi.org/10.1186/s13756-020-00875-7
Oliveira DMP, Forde BM, Kidd TJ, Harris PNA, Schembri MA, Beatson SA, et al. Antimicrobial Resistance in ESKAPE Pathogens. Clinical Microbiology Reviews. 2020;33(3):1–13. https://doi.org/10.1128/CMR.00181-19.
Cureño-Díaz MA, Durán-Manuel EM, Cruz-Cruz C, Ibáñez-Cervantes G, Rojo-Gutiérrez MI, Moncayo-Coello CV, et al. Impact of the modification of a cleaning and disinfection method of mechanical ventilators of COVID-19 patients and ventilator-associated pneumonia: One year of experience. American Journal of Infection Control. 2021;49(12):1474–80. https://doi.org/ 10.1016/j.ajic.2021.09.012.
Bonomo RA, Burd EM, Conly J, Limbago BM, Poirel L, Segre JA, et al. Carbapenemase-Producing Organisms: A Global Scourge. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2018;66(8):1290–7. https://doi.org/10.1093/cid/cix893.
Nordmann P, Poirel L. Epidemiology and Diagnostics of Carbapenem Resistance in Gram-negative Bacteria. Clinical Infectious Diseases. 2019;69(7):S521–8. https://doi.org/10.1093/cid/ciz824.
Guo Y, Song G, Sun M, Wang J, Wang Y. Prevalence and Therapies of Antibiotic-Resistance in Staphylococcus aureus. Frontiers in Cellular and Infection Microbiology. 2020;10(1):1–11. https://doi.org/10.3389/fcimb.2020.00107.
Vestergaard M, Frees D, Ingmer H. Antibiotic Resistance and the MRSA Problem. Microbiology Spectrum. 2019;7(2):1–23. https://doi.org/10.1128/microbiolspec.gpp3-0057-2018.
Russo A, Gavaruzzi F, Ceccarelli G, Borrazzo C, Oliva A, Alessandri F, et al. Multidrug-resistant Acinetobacter baumannii infections in COVID-19 patients hospitalized in intensive care unit. Infection. 2021;50(1):83–92. https://doi.org/10.1007/s15010-021-01643-4.
Montrucchio G, Corcione S, Lupia T, Shbaklo N, Olivieri C, Poggioli M, et al. The Burden of Carbapenem-Resistant Acinetobacter baumannii in ICU COVID-19 Patients: A Regional Experience. Journal of Clinical Medicine. 2022;11(17):5208. https://doi.org/10.3390/jcm11175208.
Polly M, de Almeida BL, Lennon RP, Cortês MF, Costa SF, Guimarães T. Impact of the COVID-19 pandemic on the incidence of multidrug-resistant bacterial infections in an acute care hospital in Brazil. American Journal of Infection Control. 2022;50(1):32–8. https://doi.org/10.1016/j.ajic.2021.09.018.
Aslam S, Asrat H, Liang R, Qiu W, Sunny S, Maro A, et al. Methicillin-resistant Staphylococcus aureus bacteremia during the coronavirus disease 2019 (COVID-19) pandemic: Trends and distinguishing characteristics among patients in a healthcare system in New York City. Infection Control & Hospital Epidemiology. 2022;1–3. https://doi.org/10.1017/ice.2022.238.
Habib G, Mahmood K, Gul H, Tariq M, Ain QU, Hayat A, et al. Pathophysiology of Methicillin-Resistant Staphylococcus aureus Superinfection in COVID-19 Patients. Pathophysiology. 2022;29(3):405–13. https://doi.org/10.3390/pathophysiology29030032.
Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clinical Microbiology and Infection. 2020;26(12):1622–9. https://doi.org/10.1016/j.cmi.2020.07.016.
Souza SCS, Silva DF da, Belei RA, Carrilho CMD de M. Fatores associados à mortalidade de pacientes com enterobactéria resistente aos carbapenêmicos. Medicina (Ribeirão Preto) [Internet]. 2 de abril de 2016 [citado 23 de outubro de 2022];49(2):109-15. Disponível em: https://www.revistas.usp.br/rmrp/article/view/118394
Zhen X, Stålsby Lundborg C, Sun X, Zhu N, Gu S, Dong H. Economic burden of antibiotic resistance in China: a national level estimate for inpatients. Antimicrobial Resistance & Infection Control. 2021;10(5):1–9. https://doi.org/10.1186/s13756-020-00872-w.
Burki TK. Superbugs: An Arms Race Against Bacteria. The Lancet Respiratory Medicine. 2018;6(9):668. https://doi.org/10.1016/s2213-2600(18)30271-6.
Li P, Li Y, Zhang Y, Bao J, Yuan R, Lan H, et al. Economic burden attributable to healthcare-associated infections in tertiary public hospitals of Central China: a multi-centre case-control study. Epidemiology and Infection. 2022;150(1):1–4. https://doi.org/10.1017/s0950268822001340.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Edlainny Araujo Ribeiro, Mateus Pereira Mundoca, Mateus Taborda Cachoeira, Luana Lopes Nobre, Marcia Juciele da Rocha
This work is licensed under a Creative Commons Attribution 4.0 International License.
